A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study (NCT04641247)
An Open-Label, Multicenter, Long-term Treatment Extension Study in Subjects Who Have Completed a Prior GlaxoSmithKline/TESARO-Sponsored Niraparib Study and Are Judged by the Investigator to Benefit From Continued Treatment With Niraparib
🩺 Plain-English Summary (8th-Grade Level)
This is a global extension study to provide continued access to niraparib and further characterize the long-term safety of niraparib treatment in participants who are currently receiving treatment with niraparib within GlaxoSmithKline/TESARO-sponsored studies (NCT01847274, NCT02354586, NCT01905592, NCT03308942, NCT02657889) that has fulfilled the requirements for the primary objective.
Who can join: Review the eligibility criteria below.
Location: GSK Investigational Site — Tucson, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (25 Sites)
- GSK Investigational Site — Tucson, Arizona
- GSK Investigational Site — Encinitas, California
- GSK Investigational Site — Los Angeles, California
- GSK Investigational Site — Whittier, California
- GSK Investigational Site — Jacksonville, Florida
- GSK Investigational Site — Atlanta, Georgia
- GSK Investigational Site — Harvey, Illinois
- GSK Investigational Site — Boston, Massachusetts
- GSK Investigational Site — Grand Rapids, Michigan
- GSK Investigational Site — Morristown, New Jersey
- GSK Investigational Site — Lake Success, New York
- GSK Investigational Site — Charlotte, North Carolina
- GSK Investigational Site — Cleveland, Ohio
- GSK Investigational Site — Graz,
- GSK Investigational Site — Vienna,
- GSK Investigational Site — Kelowna, British Columbia
- GSK Investigational Site — Toronto, Ontario
- GSK Investigational Site — Montreal, Quebec
- GSK Investigational Site — Odense C,
- GSK Investigational Site — Nantes,
- GSK Investigational Site — Nice,
- GSK Investigational Site — Haifa,
- GSK Investigational Site — Cremona,
- GSK Investigational Site — Madrid,
- GSK Investigational Site — Madrid,
📞 Contact the Study Coordinator
Phone: (877) 379-3718
Email: GSKClinicalSupportHD@gsk.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Ovarian Neoplasms
- A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy — Tempe, Arizona
- A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer — Anchorage, Alaska
- BMX-001 + Paclitaxel in Adult Patients With Advanced, Recurrent, Metastatic Ovarian or Endometrial Cancer — Durham, North Carolina
- Ovarian Cancer Liquid Biopsy for Early Assessment & Detection in Individuals With BRCA1/2 Pathogenic Variants — New York, New York
- Developing a Test of Uterine Lavage for the Detection of Ovarian Cancer — Little Rock, Arkansas
- A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01) — Randwick, New South Wales
Explore by condition: All Ovarian Neoplasms clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.